TY - JOUR AU - Nason, Gregory J. AU - Sweet, Joan AU - Landoni, Lauren AU - Leao, Ricardo AU - Anson-Cartwright, Lynn AU - Mok, Spencer AU - Guzylak, Vanessa AU - D’Angelo, Andrea AU - Fang, Zhi Yi AU - Geist, Ilana AU - Warde, Padraig AU - Jewett , Michael A.S. AU - Hamilton, Robert J. PY - 2020/06/16 Y2 - 2024/03/28 TI - Discrepancy in pathology reports upon second review of radical orchiectomy specimens for testicular germ cell tumors JF - Canadian Urological Association Journal JA - CUAJ VL - 14 IS - 12 SE - Original Research DO - 10.5489/cuaj.6481 UR - https://cuaj.ca/index.php/journal/article/view/6481 SP - 411-5 AB - <p><strong>Introduction:</strong> We sought to evaluate the discrepancies between primary pathology report and second pathology review of radical orchiectomy (RO) specimens.</p><p><strong>Methods:</strong> A retrospective review was performed of RO specimens from the Ontario Cancer Registry. All cases required both a primary pathology report and a second pathology review from another institution. Histopathological variables assessed included histological subtype and components of mixed germ cell tumor (GCT), pathological tumor (pT) stage, lymphovascular invasion (LVI), spermatic cord invasion, and surgical margin.</p><p><strong>Results:</strong> Between 1994 and 2015, 5048 ROs were performed with 2719 (53.9%) seminoma and 2029 (40.2%) non-seminoma. Of these, 519 (10.3%) received a second pathology review. There was concordance between primary pathology report and second pathology review in 326 (62.8%) cases. The most common discrepancies involved a change in pT stage (n=148, 28.5%), with upstaging in 83 (16%) and downstaging in 65 (12.5%) cases relative to the original pT stage. The second most common discrepancy regarded the reporting of LVI (n=121, 23.3%), with 62 (11.9%) reporting presence of LVI when the primary pathology report did not. Other discrepancies included a change in the histological subtype in 28 (5.4%) cases and spermatic cord margin status in five (9.6%) cases.</p><p><strong>Conclusions:</strong> Only 10% of orchiectomy specimens underwent a second pathology review, with nearly 40% of reviews leading to a meaningful change in parameters. Such variation could lead to incorrect tumor staging, estimate of relapse risk, and inappropriate treatment decisions. Expert pathology review of RO specimens should be considered, as it has significant implications for decision-making.</p> ER -